1. Home
  2. CPAY vs BIIB Comparison

CPAY vs BIIB Comparison

Compare CPAY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corpay Inc.

CPAY

Corpay Inc.

HOLD

Current Price

$316.61

Market Cap

21.7B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$182.40

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPAY
BIIB
Founded
1986
1978
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7B
24.2B
IPO Year
2010
1991

Fundamental Metrics

Financial Performance
Metric
CPAY
BIIB
Price
$316.61
$182.40
Analyst Decision
Buy
Buy
Analyst Count
11
22
Target Price
$369.64
$177.40
AVG Volume (30 Days)
516.4K
2.3M
Earning Date
02-04-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
5.04
N/A
EPS
14.72
10.97
Revenue
$4,314,608,000.00
$10,065,900,000.00
Revenue This Year
$15.86
$3.58
Revenue Next Year
$15.55
N/A
P/E Ratio
$20.97
$15.91
Revenue Growth
11.27
4.77
52 Week Low
$252.84
$110.04
52 Week High
$400.81
$185.17

Technical Indicators

Market Signals
Indicator
CPAY
BIIB
Relative Strength Index (RSI) 61.48 64.16
Support Level $298.00 $171.61
Resistance Level $316.01 $178.46
Average True Range (ATR) 7.01 4.07
MACD -0.88 -0.08
Stochastic Oscillator 94.76 99.46

Price Performance

Historical Comparison
CPAY
BIIB

About CPAY Corpay Inc.

Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. Its suite of modern payment solutions helps customers manage vehicle-related expenses, lodging expenses, and corporate payments. Its reportable segments are; Vehicle Payments, Corporate Payments, Lodging Payments, and Other. The group's geographic areas are the United States, Brazil, the United Kingdom, and Other.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: